{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"HilleVax, Inc."},"Symbol":{"label":"Symbol","value":"HLVX"},"Address":{"label":"Address","value":"75 STATE STREET,SUITE 100 - 9995 SUITE 100 - NO. 9995, BOSTON, Massachusetts, 02109, United States"},"Phone":{"label":"Phone","value":"+1 617 213-5054"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection."},"CompanyUrl":{"label":"Company Url","value":"https://www.hillevax.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Anju Chatterji","title":"Chief Technology Officer"},{"name":"Astrid Borkowski","title":"Chief Medical Officer"},{"name":"Robert M. Hershberg","title":"Chairman, President & Chief Executive Officer"},{"name":"Sean McLoughlin","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}